Bellerophon Therapeutics Inc. (NASDAQ:BLPH) – Stock analysts at SunTrust Banks lifted their FY2016 earnings per share (EPS) estimates for Bellerophon Therapeutics in a report issued on Thursday. SunTrust Banks analyst E. Nash now forecasts that the firm will post earnings of ($1.50) per share for the year, up from their prior estimate of ($1.60). SunTrust Banks also issued estimates for Bellerophon Therapeutics’ Q4 2016 earnings at ($0.28) EPS, FY2017 earnings at ($1.08) EPS and FY2018 earnings at ($0.96) EPS.

Several other research analysts also recently weighed in on BLPH. Zacks Investment Research downgraded shares of Bellerophon Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 15th. Cowen and Company restated a “buy” rating on shares of Bellerophon Therapeutics in a report on Thursday, August 11th.

Earnings History and Estimates for Bellerophon Therapeutics (NASDAQ:BLPH)

Shares of Bellerophon Therapeutics (NASDAQ:BLPH) opened at 1.0201 on Monday. Bellerophon Therapeutics has a 1-year low of $0.86 and a 1-year high of $4.58. The stock’s 50 day moving average is $1.29 and its 200-day moving average is $1.55. The firm’s market cap is $14.89 million.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.

5 Day Chart for NASDAQ:BLPH

Receive News & Stock Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related stocks with our FREE daily email newsletter.